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Abstract 
Aims:  Recent guidelines recommend that patients with heart failure and left ventricular ejection 
fraction (LVEF) 40-49% should be managed similar to LVEF ≥50%.  We investigated the effect 
of beta-blockers according to LVEF in double-blind, randomised, placebo-controlled trials. 
Methods and Results:  Individual patient data meta-analysis of eleven trials, stratified by 
baseline LVEF and heart rhythm (Clinicaltrials.gov:NCT0083244; 
PROSPERO:CRD42014010012).  Primary outcomes were all-cause mortality and 
cardiovascular death over 1.3 years median follow-up, with an intention-to-treat analysis.  For 
14,262 patients in sinus rhythm, median LVEF was 27% (interquartile range 21-33%), including 
575 patients with LVEF 40-49% and 244 ≥50%.  Beta-blockers reduced all-cause and 
cardiovascular mortality compared to placebo in sinus rhythm, an effect that was consistent 
across LVEF strata, except for those in the small subgroup with LVEF ≥50%.  For LVEF 40-
49%, death occurred in 21/292 [7.2%] randomised to beta-blockers compared to 35/283 [12.4%] 
with placebo; adjusted hazard ratio (HR) 0.59 (95% CI 0.34-1.03).  Cardiovascular death 
occurred in 13/292 [4.5%] with beta-blockers and 26/283 [9.2%] with placebo; adjusted HR 
0.48 (95% CI 0.24-0.97).  Over a median of 1.0 years following randomisation, LVEF increased 
with beta-blockers in all groups in sinus rhythm except LVEF ≥50% (n=4,601).  For patients in 
atrial fibrillation at baseline (n=3,050), beta-blockers increased LVEF when <50% at baseline, 
but did not improve prognosis. 
Conclusion:  Beta-blockers improve LVEF and prognosis for patients with heart failure in sinus 
rhythm with a reduced LVEF.  The data are most robust for LVEF <40%, but similar benefit 
was observed in the subgroup of patients with LVEF 40-49%. 
Key Words:  Heart failure; Ejection fraction; Heart failure; Beta-blockers; Mortality. 
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Introduction 
Double-blind, randomised, placebo-controlled trials (RCTs) show that beta-blockers increase 
left ventricular ejection fraction (LVEF) and reduce morbidity and mortality for a broad range of 
patients with a reduced LVEF in sinus rhythm.1, 2  Until recently, international guidelines on 
heart failure have recognized two left ventricular phenotypes; heart failure with reduced LVEF 
(HFrEF) or preserved LVEF (HFpEF).3, 4  Values for LVEF are continuously distributed but 
measurement precision is imperfect; differences of up to 10% for an individual patient may be 
attributed to measurement error5 and therefore precise cut-points of LVEF cannot reliably 
differentiate between phenotypes.  Recently, the European Society of Cardiology (ESC) 
suggested there should be a third intermediate phenotype, called mid-range ejection fraction 
(HFmrEF; 40-49%), thereby creating a clear separation between HFrEF (<40%) and HFpEF 
(≥50%).4  These guidelines suggest that until more information becomes available, patients with 
HFmrEF should be managed similarly to those with HFpEF, for which no therapy has been 
shown to improve mortality.4  
 
The Beta-blockers in Heart Failure Collaborative Group (BB-meta-HF) was created to pool 
individual patient data (IPD) from the major heart failure RCTs comparing beta-blockers and 
placebo to address key issues in relevant patient subgroups.6  Most, but not all of these trials 
recruited patients with an LVEF <35% predominantly in sinus rhythm; IPD provides an 
opportunity to collate high-quality data from double-blind trials on the smaller number of 
patients with higher LVEF where the efficacy of beta-blockers is uncertain.  Why beta-blockers 
appear ineffective in patients with heart failure and concomitant atrial fibrillation (AF)2, 7, 8, and 
whether this holds true regardless of LVEF is also unclear.  In this paper, we investigate the 
effect of beta-blockers on LVEF and prognosis, stratified according to baseline LVEF and heart 
rhythm.    
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Methods 
The Beta-blockers in Heart Failure Collaborative Group (BB-meta-HF) includes the lead 
investigators from the relevant trials, with the support of the four pharmaceutical companies that 
conducted them (AstraZeneca, GlaxoSmithKline, Merck Serono and Menarini).  This report was 
prepared according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) IPD guidance9, and prospectively registered with Clinicaltrials.gov (NCT0083244) 
and the PROSPERO database of systematic reviews (CRD42014010012).10   
 
Eligibility & search strategy 
Detailed rationale and methods have previously been published.1, 6, 7  Only unconfounded 
placebo-controlled trials were eligible that recruited >300 patients, with a planned follow-up of 
>6 months and explicit reporting of mortality.  All trials had appropriate ethical approval. 
Eleven studies were included that account for 95.7% of eligible participants recruited in RCTs 
based on a systematic literature review: the Australia/New Zealand Heart Failure Study 
(ANZ)11, the Beta-Blocker Evaluation Survival Trial (BEST)12, the Carvedilol Post-Infarct 
Survival Control in LV Dysfunction Study (CAPRICORN)13, the Carvedilol Hibernating 
Reversible Ischaemia Trial: Marker of Success Study (CHRISTMAS)14, the Cardiac 
Insufficiency Bisoprolol Study (CIBIS I)15, the Cardiac Insufficiency Bisoprolol Study II 
(CIBIS-II)16, the Carvedilol Prospective Randomized Cumulative Survival Study 
(COPERNICUS)17, the Metoprolol in Idiopathic Dilated Cardiomyopathy Study (MDC)18, the 
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)19, 
the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors 
with Heart Failure (SENIORS)20 and the U.S. Carvedilol Heart Failure Program (US-HF).21   
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All included studies had low risk of bias, as determined using the Cochrane Collaborations Risk 
of Bias Tool.22   
 
Data collection & IPD integrity 
A standardized data request form to obtain IPD from each trial has been published, along with 
search results and individual study demographics.6  IPD were obtained for all eleven trials 
identified in the systematic review, and data were extracted from original source files provided 
by the pharmaceutical companies and lead investigators.  All data were cross-checked across 
different trial databases and compared with published reports.  Discrepancies, inconsistencies 
and incomplete data were checked against original case report forms and trial documentation to 
ensure IPD integrity.  All eleven trial databases were then harmonized according to the 
standardized data request form to match patient characteristics and outcomes across all trials.  
Due to the small amount of missing data for relevant covariates, imputation was not performed.   
 
Participants 
We included all patients with baseline LVEF and an electrocardiogram (ECG) that showed 
either sinus rhythm or AF/atrial flutter (for the purposes of this report, reference to AF therefore 
includes atrial flutter).  As we have already demonstrated an interaction of treatment effect with 
heart rhythm7, patients with sinus rhythm and AF were analysed separately.  Patients with heart 
block, or a paced rhythm at baseline were excluded.   
 
Outcomes & effect measures 
The primary outcomes for this analysis were all-cause mortality and cardiovascular death, which 
included additional deaths reported after the censor date for seven studies.19-21, 25, 26, 28, 29  
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Secondary outcomes were the first cardiovascular hospitalization and the composite of 
cardiovascular death and cardiovascular hospitalization (time to first event).  All secondary 
outcomes were based on events from the study period only and do not include the MDC trial 
which did not collect this information.  Three patients (one with sinus rhythm and two with AF) 
had missing event dates and were excluded from outcome analyses. 
 
Most of the trials had limits for LVEF as inclusion or exclusion criteria, however these were 
typically defined preceding randomization (<25%17, ≤35%12, 16, 21, ≤40%13, 15, 18, 19 and <45%11; 
Supplementary Figure A).  In this analysis, we used the baseline value of LVEF recorded in 
individual patient case report forms or core laboratory assessment, which in some patients was 
above the entry criterion according to that particular study.  LVEF was analysed as a continuous 
variable to model interactions with outcomes, and classified as <20%, 20-25%, 26-34%, 35-
39%, 40-49% and ≥50%, as well as <40%, 40-49%, ≥50% to align with guideline phenotypes.   
 
Statistical analysis 
A statistical analysis plan was generated and finalized by the Collaborative Group in advance of 
data analysis.  Summary results are presented as percentages, or median and interquartile range 
(IQR; displayed as 25th to 75th quartiles). 
All analyses followed the principle of intention-to-treat.  Patients were classified by heart 
rhythm and LVEF.  Outcomes were analysed using a Cox proportional hazards regression 
model23, stratified by study.  This is a one-stage fixed effects approach and assumes that all 
trials are estimating a common treatment effect with baseline hazards that vary across studies.  
Fractional polynomials were used to find the best transformation24, although a linear relationship 
with mortality was the best fit.  Hazard ratios (HR) and 95% confidence intervals (CI) are 
presented, along with corresponding p-values.  We pre-specified adjustment in Cox models for 
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age, sex, systolic blood pressure, prior myocardial infarction, and baseline use of angiotensin 
converting enzyme inhibitors or angiotensin receptor blockers, and diuretic therapy.  
Adjustments for treatment allocation and LVEF were also made where appropriate.  Kaplan-
Meier plots were used to graph the pooled, unadjusted trial data, with log-rank tests for 
comparison stratified by study.  Only a minority of patients were followed for more than three 
years and therefore data were censored at 1200 days (3.3 years) from randomization.  Pre-
defined sensitivity analyses included additional multivariable adjustment (including diabetes, 
NYHA class (I/II vs. III/IV), estimated glomerular filtration rate and digoxin); data are not 
shown as these results did not differ with our main model.  We performed a post-hoc sensitivity 
analysis which excluded patients with an LVEF reported at exactly 40% from the 40-49% (mid-
range) group.  A post-hoc analysis of cardiovascular hospitalisation accounting for the 
competing risk of death was performed using the method of Fine and Gray25; results were 
similar to the results of the stratified Cox regression model. 
We show the association between baseline LVEF and all cause-mortality by plotting the hazard 
of baseline LVEF relative to a baseline LVEF of 35%, fitted using an adjusted Cox proportional 
hazards model stratified by study.  Follow-up LVEF was available in six trials.11, 12, 14, 18, 20, 21  
We used the last available result to calculate change in LVEF from baseline.  As availability of 
follow-up LVEF is determined by survival, we chose not to perform any statistical hypothesis 
testing.   
There was no evidence of violation of the proportional hazards assumption in any multivariable 
model as determined by Schoenfeld residuals.26  Effect modification was assessed using p-
values from interaction terms fitted in the multivariable models.24, 27  A two-tailed p-value of 
0.05 was considered statistically significant.  Analyses were performed on Stata Version 14.1 
(StataCorp LP, Texas) and R Version 3.2.1 (R Core Team, Vienna). 
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Results 
Individual patient data were obtained for 18,637 patients. Patients were excluded if they had a 
missing baseline electrocardiogram (n=118), heart block (n=510), paced rhythm (n=616) or 
were missing their baseline LVEF (n=91).  The cohort included 14,262 patients in sinus rhythm 
and 3,050 patients in atrial fibrillation (Supplementary Figure A), with a mean follow-up of 
1.5 years (SD 1.1) and median follow-up of 1.3 years (IQR 0.8-1.9).  Median age was 65 (IQR 
55-72) years, 24% were women and 66% had ischaemic heart disease (IHD) as the cause for 
heart failure.  Median LVEF at baseline was 27% (21-33%) and was similar for patients in sinus 
rhythm (Table 1) and AF (Supplementary Table A).  Combining both heart rhythms, 721 
patients had an LVEF 40-49% and 317 had an LVEF ≥50%.  Patients with a higher baseline 
LVEF were older, more likely to be women, have milder NYHA class, higher blood pressure, 
and were less likely to have heart failure due to IHD.  There were no differences in patient 
characteristics between those assigned to beta-blockers or placebo (Supplementary Table B). 
 
LVEF at baseline was inversely associated with all-cause mortality, with an adjusted HR of 1.16 
for each 5% lower LVEF (95% CI 1.26-1.19; p<0.0001).  Figure 1 displays the hazard of all-
cause mortality with LVEF 35% as the reference.  The association between LVEF and prognosis 
was stronger for patients in sinus rhythm than AF (Supplementary Table C).  Patients with 
LVEF ≥50% had the lowest mortality despite their older age (Supplementary Figure B); all-
cause and cardiovascular mortality were 10.4% and 6.3% respectively for those with LVEF 
≥50%, compared to 26.7% and 21.7% for those with LVEF <20%.  Mortality was 
predominantly cardiovascular regardless of aetiology, both for patients in sinus rhythm 
(Supplementary Table D) and AF (Supplementary Table E), and mostly attributed to sudden 
death or worsening heart failure. 
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Beta-blockers were associated with reductions in all-cause and cardiovascular mortality 
compared to placebo for patients in sinus rhythm (interaction p>0.5 for LVEF as a continuous 
measure).  Beta-blockers were effective in all LVEF categories, except in the small subgroup 
where LVEF was ≥50% (Table 2 and Figure 2).  There was no evidence for a difference in 
benefit when LVEF was 40-49%; all-cause mortality occurred in 21/292 [7.2%] randomised to a 
beta-blockers compared to 35/283 [12.4%] assigned to placebo (adjusted HR 0.59, 95% CI 0.34-
1.03), and cardiovascular death in 13/292 [4.5%] with beta-blockers and 26/283 [9.2%] with 
placebo; (adjusted HR 0.48, 95% CI 0.24-0.97) (Figure 3).  Beta-blockers reduced both sudden 
death and deaths ascribed to heart failure for patients in sinus rhythm, but had no effect on non-
cardiovascular mortality (Supplementary Table D).  Secondary outcomes (cardiovascular 
hospitalization and the composite of cardiovascular death and cardiovascular hospitalization) 
were lower with beta-blockers in all LVEF categories for patients in sinus rhythm, but 
confidence intervals were wide when LVEF exceeded 40% (Table 2 and Figure 2). 
   
Patients with AF at baseline demonstrated no consistent benefit on clinical outcomes with beta-
blockers, regardless of LVEF (Figure 4).  Fewer patients and events reduced the power to 
identify or refute modest differences in outcome.   
 
Change in LVEF was measured in 4,601 patients in sinus rhythm and 996 patients in AF who 
survived to a follow-up assessment (median 1.0 years after baseline; IQR 0.3-2.0) 
(Supplementary Figure C).  In sinus rhythm, LVEF increased more in patients randomized to 
beta-blockers than placebo, unless LVEF was ≥50% at baseline (Table 3 and Figure 5).  
Increases in LVEF with beta-blockers were smaller for patients with IHD as the cause for heart 
failure compared to non-ischaemic cardiomyopathy (Supplementary Table F).  Beta-blockers 
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also increased LVEF for patients in AF in most LVEF categories except ≥50% (Table 3 and 
Figure 5).   1  2 
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Discussion 
This analysis suggests that for patients with heart failure in sinus rhythm, the effect of beta-
blockers on mortality in patients with LVEF 40-49% is similar to that observed with LVEF 
<40%.  Consistent with the outcome data, LVEF increased with beta-blockers in all groups, 
except those with LVEF ≥50%.  Only the SENIORS trial20 intentionally enrolled patients with 
any LVEF, but despite showing efficacy for beta-blockers in those with LVEF >35%28, there 
were too few patients and events to draw any conclusions in patients with more preserved 
LVEF.  The lower the LVEF, the higher the rate of adverse outcomes and therefore the benefit 
of beta-blockers might be expected to be greatest in those with lower LVEF, as seen in a 
subgroup analysis of the MERIT-HF trial.29  However, we demonstrate a substantial 4.7% 
absolute reduction in cardiovascular mortality in patients with LVEF 40-49% and sinus rhythm 
(number needed to treat to prevent one cardiovascular death = 21 during a median follow-up of 
1.3 years).  This finding was statistically significant despite the relatively low number of trial 
patients studied in this LVEF category.  Our preference in statistical analysis is always to report 
the interaction of treatment effect across continuous variables such as LVEF, instead of relying 
on efficacy in subgroups.  However in this case, the data are dominated by patients with LVEF 
<40% and interaction tests are known to have low power.30  Similar improvements in LVEF 
were seen for those in AF, but this did not translate into better outcomes with beta-blockers for 
patients in AF.  
 
The mechanisms by which beta-blockers exert benefit are uncertain.2  Blocking adrenergic 
receptors has direct effects on cardiomyocytes, reduces heart rate, alters vascular function and 
modifies the neuro-endocrine response to heart failure.31  The importance of these mechanisms 
may vary by aetiology, left ventricular phenotype, heart rhythm and clinical indication.  For 
example, beta-blockers are recommended for the treatment of ventricular tachycardia and 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 13 of 35 
prevention of ventricular fibrillation in the context of an acute coronary syndrome32, but may 
have deleterious effects compared to other therapy in hypertension or non-cardiac surgery.33  An 
improvement in LVEF is usually considered evidence of therapeutic benefit, but this analysis 
suggests we should be cautious about making such assumptions.  The increase in LVEF with 
beta-blockers was smaller for patients with IHD, but the benefit on mortality was similar to 
those with a non-ischaemic cause for heart failure.  The increase in LVEF with beta-blockers 
was similar for patients in sinus rhythm and AF, yet those with AF obtained no benefit on 
morbidity or mortality.  The underlying reasons for this discrepancy remains a subject of 
discussion4, 8, and the increase in both incidence and prevalence of AF34 highlights a growing 
unmet clinical and research need.  
 
Recent guidelines from the ESC suggest that left ventricular dysfunction should be classified as 
HFrEF when LVEF is <40%, HFmrEF when 40-49% and HFpEF only when LVEF is 50% or 
greater.4  The guideline points out that trials have, until recently, mostly used an LVEF of 40% 
or 45% to define HFpEF and none have identified an intervention that reduced morbidity or 
mortality for such patients.4  Accordingly, the guideline recommends that patients with HFmrEF 
be managed in the same way as HFpEF until new evidence becomes available.  Interestingly, a 
post-hoc analysis of the Treatment of Preserved cardiac function heart failure with an 
Aldosterone antagonist Trial (TOPCAT) also suggested a reduction in cardiovascular mortality 
with spironolactone in patients with an investigator-recorded LVEF 45-49%, but not when 
LVEF was greater than this.35  Initial data from the Candesartan in Heart failure - Assessment of 
moRtality and Morbidity (CHARM) program of trials suggests that angiotensin inhibition has a 
similar benefit in patients with LVEF 40-49% as with <40%.36  In line with our data, it is 
possible that future guideline recommendations for patients with this intermediate phenotype 
should be more similar to those for HFrEF than HFpEF, and that the threshold for differences in 
heart failure therapy should be at, or around, an LVEF of 50%.   
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This analysis has limitations, with varied design and objectives of the component trials and 
relatively sparse outcome data for patients with LVEF >40%.  The distribution of LVEF was not 
normal due to the inclusion criteria of the component RCTs; although the 40-49% group was 
weighted towards the lower end of mid-range LVEF, we found that primary outcomes were 
reduced in this group in sinus rhythm even when excluding those with an LVEF of 40%.  In any 
trial, there is concern about whether the patients enrolled reflect the population encountered in 
clinical practice due to selection criteria, and this analysis is no different.  However, our data 
represent the vast majority of patients enrolled in double-blind RCTs of beta-blockers.   
Our use of individual-patient baseline LVEF, rather than the screening LVEF that qualified for 
inclusion, meant that most trials contributed some data to the LVEF 40-49% group.  Although 
the SENIORS trial, with a distinct type of beta-blocker, was the only RCT to specifically recruit 
patients with higher LVEF, it only accounted for 44% of patients in this category.  In trials of 
HFrEF, LVEF measured in a core echocardiography laboratory will exceed the LVEF inclusion 
criterion in 20-40% of patients.37-40  Some of the differences between the core laboratory and 
investigators may be explained by measurement error, but there also appears to be a bias on the 
part of investigators, conscious or unconscious, towards measuring an LVEF that allows for 
patient inclusion.  Regression towards the mean will also result in repeat measures being less 
extreme; thus our approach of using double-blind data will have reduced, but not eliminated 
measurement bias and inadvertent misclassification.  Both in research trials and clinical practice, 
measurements such as LVEF have inherent variability that require clinical review and oversight.   
Reported measurements such as blood pressure and LVEF are prone to digit preference (e.g. 
40% rather than 39%) and variability in timing, technique and quantification.  The impact of this 
can be lessened by including a large amount of raw data (see Supplementary Figure C) or by 
using, where available, software generated LVEF (e.g. by Teichholz or Simpson’s biplane 
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method) rather than an ‘eyeball’ assessment.  Patients who died had no follow-up LVEF and 
therefore this could have introduced bias in measured changes in LVEF.   
Determination of LVEF may be less accurate for patients in AF due to variability in cardiac 
cycle length.41  The smaller number of patients with AF, although large in comparison to many 
published interventional trials42, limits our ability to make detailed comparisons to patients in 
sinus rhythm.  Finally, data on natriuretic peptides, diastolic ventricular filling dynamics and 
atrial structure and function were lacking, which often help to describe different heart failure 
phenotypes.  
 
Conclusion 
For patients with heart failure in sinus rhythm and LVEF <40%, beta-blockers improve left 
ventricular systolic function and reduce cardiovascular morbidity and mortality.  These benefits 
also apply to patients with LVEF 40-49%, a group in which beta-blocker therapy seems more 
likely to help than to harm.  No benefit was seen in patients with LVEF ≥50%, but too few 
patients have been studied in double-blind RCTs to draw firm conclusions on the efficacy or 
safety of beta-blockers for HFpEF.  No consistent evidence of prognostic benefit was observed 
for patients with heart failure and concomitant AF.    
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Table 1: Baseline characteristics for patients in sinus rhythm 
Characteristic 
Left ventricular ejection fraction at baseline 
<20% 
N = 2553 
20-25% 
N = 3885 
26-34% 
N = 5076 
35-39% 
N = 1929 
40-49% 
N = 575 
≥50% 
N = 244 
LVEF, median (IQR) 0.15 (0.13 - 0.18)  0.23 (0.21 - 0.24)  0.30 (0.28 - 0.32)  0.36 (0.35 - 0.38) 0.40 (0.40 - 0.43) 0.58 (0.53 - 0.65) 
Age, median years (IQR) 61 (51 - 69) 63 (54 - 71) 64 (55 - 71) 64 (56 - 72) 71 (61 - 75) 75 (72 - 78) 
Women, n (%) 521 (20.4%) 886 (22.8%) 1272 (25.1%) 518 (26.9%) 198 (34.4%) 129 (52.9%) 
Years with HF diagnosis, median (IQR) 3 (1 - 6) 3 (1 - 6) 2 (1 - 5) 2 (1 - 5) 2 (1 - 5) 2 (1 - 5) 
Ischaemic HF aetiology, n (%) 1484 (58.1%) 2572 (66.2%) 3475 (68.5%) 1562 (81.0%) 522 (90.8%) 209 (85.7%) 
Prior myocardial infarction, n (%) 1242 (48.7%) 2187 (56.4%) 2993 (59.2%) 1374 (71.4%) 412 (71.8%) 88 (36.1%) 
Diabetes Mellitus, n (%) 575 (25.1%) 956 (26.0%) 1153 (23.9%) 409 (22.2%) 135 (24.1%) 71 (29.1%) 
NYHA class III/IV, n (%) 1624 (82.1%) 2045 (77.6%) 3265 (64.8%) 721 (37.7%) 136 (24.1%) 64 (26.6%) 
Heart rate, median bpm (IQR) 84 (76 - 92)  80 (72 - 90)  78 (72 - 87)  76 (70 - 84)  76 (68 - 82)  75 (68 - 83)  
Systolic BP, median mmHg (IQR) 114 (104 - 127) 120 (110 - 136) 127 (115 - 140) 130 (116 - 140) 131 (120 - 145) 147 (132 - 160) 
Diastolic BP, median mmHg (IQR) 72 (66 - 80) 77 (70 - 82) 79 (70 - 83) 80 (70 - 83) 80 (70 - 85) 82 (78 - 90) 
Body mass index, median kg/m2 (IQR) 27 (24 - 32) 27 (24 - 31) 27 (24 - 31) 27 (25 - 30) 27 (25 - 30) 27 (24 - 31) 
Estimated GFR, median mL/min (IQR) 62 (50 - 76) 61 (48 - 75) 66 (53 - 80) 65 (53 - 78) 66 (53 - 78) 69 (55 - 83) 
Any diuretic therapy, n (%) 2410 (94.4%) 3547 (91.3%) 4331 (85.3%) 1273 (66.0%) 376 (65.4%) 199 (81.6%) 
ACEi or ARB, n (%) 2304 (94.8%) 3490 (94.7%) 4643 (94.8%) 1774 (95.1%) 508 (90.6%) 203 (87.3%) 
Aldosterone antagonists, n (%) 207 (8.8%) 381 (10.4%) 360 (7.5%) 85 (4.7%) 31 (5.8%) 27 (11.9%) 
Digoxin, n (%) 1833 (73.8%) 2297 (60.4%) 2475 (49.9%) 555 (29.6%) 138 (25.6%) 48 (21.2%) 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats/minute; GFR, glomerular filtration rate; HF, heart failure; IQR, 
interquartile range; LVEF, left-ventricular ejection fraction; NYHA, New York Heart Association.   
Missing data report: n=2828 for years with HF diagnosis; n=30 for prior myocardial infarction; n=809 for diabetes mellitus; n=1504 for NYHA class; n=62 for systolic BP; n=67 for 
diastolic BP; n=8 heart rate; n=123 for body mass index; n=664 for GFR; n=918 for aldosterone antagonists; n=376 for digoxin.     
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Table 2: Beta-blockers versus placebo according to LVEF at baseline 
Baseline heart 
rhythm and LVEF 
category 
All-cause mortality Cardiovascular death Cardiovascular hospitalization 
Composite of cardiovascular death 
or cardiovascular hospitalization 
Events / N HR (95% CI); p-value Events / N HR (95% CI); p-value Events / N HR (95% CI); p-value Events / N HR (95% CI); p-value 
S
in
u
s 
rh
y
th
m
 
<20% 623 / 2531 
0.70 (0.60-0.83); 
p<0.001 
517 / 2531 
0.67 (0.56-0.80); 
p<0.001 
762 / 2407 
0.70 (0.60-0.81); 
p<0.001 
990 / 2407 
0.68 (0.60-0.77); 
p<0.001 
20-25% 619 / 3862 
0.76 (0.65-0.89); 
p=0.001 
521 / 3862 
0.78 (0.65-0.92); 
p=0.004 
1033 / 
3807 
0.75 (0.66-0.85); 
p<0.001 
1273 / 
3807 
0.75 (0.67-0.84); 
p<0.001 
26-34% 631 / 5043 
0.75 (0.64-0.88); 
p<0.001 
504 / 5042 
0.73 (0.61-0.87); 
p<0.001 
1118 / 
4972 
0.84 (0.74-0.94); 
p=0.003 
1384 / 
4972 
0.80 (0.72-0.88); 
p<0.001 
35-39% 189 / 1919 
0.67 (0.50-0.90); 
p=0.007 
156 / 1919 
0.72 (0.52-0.99); 
p=0.041 
401 / 1907 
0.75 (0.61-0.91); 
p=0.004 
490 / 1907 
0.74 (0.62-0.88); 
p=0.001 
40-49% 55 / 570 
0.59 (0.34-1.03); 
p=0.066 
38 / 570 
0.48 (0.24-0.97); 
p=0.040 
144 / 566 
0.95 (0.68-1.32);  
p=0.76 
164 / 566 
0.83 (0.60-1.13);  
p=0.23 
≥50% 24 / 241 
1.79 (0.78-4.10);  
p=0.17 
15 / 241 
1.77 (0.61-5.14);  
p=0.29 
50 / 241 
0.66 (0.37-1.18);  
p=0.16 
54 / 241 
0.66 (0.38-1.15);  
p=0.14 
          
A
tr
ia
l 
fi
b
ri
ll
a
ti
o
n
 
<20% 143 / 492 
1.23 (0.88-1.74);  
p=0.23 
124 / 492 
1.16 (0.80-1.67);  
p=0.44 
148 / 471 
0.97 (0.69-1.35);  
p=0.85 
201 / 471 
0.96 (0.72-1.28); 
p<0.001 
20-25% 159 / 867 
0.74 (0.54-1.02);  
p=0.07 
136 / 867 
0.77 (0.54-1.08);  
p=0.13 
234 / 856 
0.75 (0.58-0.98); 
p=0.032 
291 / 856 
0.75 (0.59-0.95); 
p=0.003 
26-34% 208 / 1093 
0.98 (0.74-1.29);  
p=0.87 
166 / 1093 
0.98 (0.72-1.34);  
p=0.92 
321 / 1083 
1.01 (0.81-1.26);  
p=0.92 
390 / 1083 
0.93 (0.76-1.13); 
p=0.001 
35-39% 59 / 363 
0.92 (0.53-1.58);  
p=0.75 
46 / 363 
0.67 (0.35-1.25);  
p=0.21 
99 / 358 
0.90 (0.60-1.36);  
p=0.62 
121 / 358 
0.94 (0.65-1.37); 
p=0.046 
40-49% 32 / 146 
1.30 (0.63-2.67);  
p=0.48 
22 / 146 
0.86 (0.36-2.03);  
p=0.73 
34 / 143 
1.15 (0.57-2.32);  
p=0.69 
46 / 143 
1.06 (0.58-1.94); 
p=0.040 
≥50% 8 / 73 
0.86 (0.19-3.94);  
p=0.85 
4 / 73 
1.00 (0.10-9.91);   
p=1.00 
26 / 73 
1.33 (0.56-3.16);  
p=0.52 
27 / 73 
1.17 (0.51-2.71);  
p=0.42 
CI = confidence interval; HR = Hazard ratio (adjusted for baseline characteristics and stratified by trial); LVEF = left ventricular ejection fraction; N = number of individuals.  
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Table 3: Absolute mortality difference and observed change in LVEF 
Classification ‘Reduced’ LVEF ‘Mid-range’ LVEF ‘Preserved’ LVEF 
LVEF at baseline <20% 20-25% 26-34% 35-39% 40-49% ≥50% 
Sinus rhythm: All aetiology*       
Change in absolute mortality; beta-blockers 
vs placebo (95% CI)† 
n=2552  
-6.9%  
(-10.3% to -3.5%) 
n=3885  
-3.9%  
(-6.3% to -1.6%) 
n=5076  
-3.2%  
(-5.1% to -1.4%) 
n=1929  
-3.4%  
(-6.1% to -0.7%) 
n=575  
-5.2%  
(-10.0% to -0.3%) 
n=244  
+2.3%  
(-5.3% to +9.9%) 
Change in LVEF from baseline to follow-
up; mean difference (SE) beta-blockers vs 
placebo‡ 
n=1106 
+4.7% (0.5%) 
n=1068 
+4.0% (0.5%) 
n=1600 
+4.2% (0.5%) 
n=375 
+4.9% (0.9%) 
n=251 
+1.9% (1.1%) 
n=201 
+0.1% (1.2%) 
Atrial fibrillation: All aetiology       
Change in absolute mortality; beta-blockers 
vs placebo (95% CI) † 
n=494  
+2.8%  
(-5.3% to +10.9%) 
n=867  
-4.1%  
(-9.3% to +1.1%) 
n=1101  
-0.8%  
(-5.5% to +3.9%) 
n=367  
-3.2%  
(-10.7% to +4.3%) 
n=146  
+3.2%  
(-10.4% to +16.7%) 
n=73  
+0.3%  
(-14.0% to +14.6%) 
Change in LVEF from baseline to follow-
up; mean difference (SE) beta-blockers vs 
placebo‡ 
n=177 
+4.6% (1.7%) 
n=200 
+3.4% (1.2%) 
n=369 
+1.5% (1.0%) 
n=98 
+0.1% (1.9%) 
n=93 
+4.8% (1.9%) 
n=59 
-2.2% (3.0%) 
* See Supplementary Table F for data according to ischaemic/non-ischaemic aetiology in sinus rhythm. 
† Median follow-up of 1.3 years (IQR 0.8-1.9) 
‡ Median 1.0 years after baseline assessment (IQR 0.3-2.0) 
CI = confidence interval; LVEF = left ventricular ejection fraction; SE = standard error of the mean difference. 
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Supplementary Table A: Baseline characteristics for patients in atrial fibrillation 
Characteristic 
Left ventricular ejection fraction at baseline 
<20% 
N = 494 
20-25% 
N = 868 
26-34% 
N = 1101 
35-39% 
N = 368 
40-49% 
N = 146 
≥50% 
N = 73 
LVEF, median (IQR) 0.16 (0.14 - 0.18) 0.23 (0.21 - 0.24) 0.30 (0.28 - 0.32) 0.35 (0.35 - 0.37) 0.41 (0.40 - 0.45) 0.56 (0.52 - 0.64) 
Age, median years (IQR) 66 (59 - 73) 67 (59 - 73) 69 (61 - 75) 70 (61 - 74) 75 (71 - 79) 76 (74 - 79) 
Women, n (%) 63 (12.8%) 128 (14.7%) 204 (18.5%) 86 (23.4%) 72 (49.3%) 39 (53.4%) 
Years with HF diagnosis, median (IQR) 5 (2 - 8) 4 (2 - 8) 3 (1 - 6) 3 (1 - 6) 3 (1 - 5) 1 (0 - 4) 
Ischaemic HF aetiology, n (%) 267 (54.0%) 443 (51.0%) 581 (52.8%) 233 (63.3%) 104 (71.2%) 52 (71.2%) 
Prior myocardial infarction, n (%) 218 (44.3%) 331 (38.1%) 417 (38.2%) 168 (46.0%) 43 (29.5%) 21 (28.8%) 
Diabetes Mellitus, n (%) 108 (24.2%) 200 (23.9%) 243 (22.8%) 72 (20.7%) 32 (22.7%) 19 (26.0%) 
NYHA class III/IV, n (%) 434 (88.0%) 765 (88.2%) 819 (74.7%) 209 (57.3%) 56 (38.6%) 31 (42.5%) 
Heart rate, median bpm (IQR) 84 (73 - 95) 81 (72 - 92) 80 (72 - 91) 80 (72 - 89) 82 (73 - 92) 84 (78 - 96) 
Systolic BP, median mmHg (IQR) 120 (107 - 130) 122 (110 - 138) 130 (118 - 143) 130 (120 - 145) 142 (128 - 155) 140 (130 - 153) 
Diastolic BP, median mmHg (IQR) 73 (65 - 80) 78 (70 - 82) 80 (70 - 87) 80 (72 - 87) 80 (75 - 90) 80 (79 - 89) 
Body mass index, median kg/m2 (IQR) 27 (24 - 32) 27 (24 - 31) 28 (25 - 31) 28 (25 - 31) 26 (24 - 29) 28 (26 - 31) 
Estimated GFR, median mL/min (IQR) 57 (45 - 69) 57 (46 - 70) 64 (52 - 77) 63 (50 - 75) 62 (49 - 76) 60 (49 - 78) 
Any diuretic therapy, n (%) 480 (97.2%) 833 (96.0%) 1028 (93.4%) 312 (84.8%) 131 (89.7%) 68 (93.2%) 
ACEi or ARB, n (%) 464 (93.9%) 833 (96.0%) 1036 (94.1%) 352 (95.7%) 133 (91.1%) 64 (87.7%) 
Aldosterone antagonists, n (%) 78 (16.7%) 176 (20.7%) 136 (12.6%) 62 (17.6%) 27 (18.8%) 16 (21.9%) 
Digoxin, n (%) 435 (88.1%) 749 (86.3%) 920 (83.6%) 272 (73.9%) 117 (80.1%) 52 (71.2%) 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats/minute; GFR, glomerular filtration rate; HF, heart failure; IQR, 
interquartile range; LVEF, left-ventricular ejection fraction; NYHA, New York Heart Association.   
Missing data report: n=319 for years with HF diagnosis; n=13 for prior myocardial infarction; n=135 for diabetes mellitus; n=431 for NYHA class; n= 2 for diastolic BP; n=8 heart rate; n= 22 for 
body mass index; n=101 for GFR; n=85 for any diuretic therapy; n=85 for aldosterone antagonists.      
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 28 of 35 
 
Supplementary Table B: Baseline characteristics according to randomised treatment allocation in sinus rhythm 
Characteristic 
LVEF <40% LVEF 40-49% LVEF ≥50% 
PLACEBO  
N=6582 
BETA-BLOCKER  
N=6861 
PLACEBO 
N=283 
BETA-BLOCKER 
N=292 
PLACEBO 
N=121 
BETA-BLOCKER  
N=123 
LVEF, median (IQR) 0.26 (0.20-0.32) 0.26 (0.20-0.32) 0.40 (0.40-0.44) 0.40 (0.40-0.43) 0.58 (0.52-0.65) 0.58 (0.54-0.65) 
Age, median years (IQR) 63 (54-71) 63 (54-71) 72 (61-75) 70 (60-74) 75 (72-78) 75 (71-78) 
Women, % 23.6% 24.0% 33.6% 35.3% 47.9% 57.7% 
Years with HF diagnosis, median (IQR) 3 (1-6) 3 (1-6) 2 (1-5) 2 (1-5) 2 (1-5) 2 (0-6) 
Ischaemic HF aetiology, % 67.7% 67.5% 92.6% 89.0% 86.8% 84.6% 
Prior myocardial infarction, % 58.0% 58.2% 72.3% 71.2% 39.7% 32.5% 
Diabetes Mellitus, % 24.3% 24.6% 23.0% 25.1% 30.6% 27.6% 
NYHA class III/IV, % 68.1% 67.7% 21.6% 26.5% 24.0% 29.3% 
Heart rate, median bpm (IQR) 80 (72-88) 80 (72-88) 75 (68-82) 76 (70-82) 75 (68-84) 74 (68-80) 
Systolic BP, median mmHg (IQR) 122 (110-138) 122 (110-138) 132 (120-148) 130 (120-145) 146 (132-161) 147 (132-160) 
Diastolic BP, median mmHg (IQR) 77 (70-82) 77 (70-82) 80 (70-85) 80 (70-84) 80 (79-90) 82 (77-90) 
Body mass index, median kg/m2 (IQR) 27 (24-31) 27 (24-31) 27 (25-30) 27 (25-30) 26 (24-31) 27 (25-30) 
Estimated GFR, median mL/min (IQR) 64 (52-78) 64 (51-77) 67 (53-78) 66 (53-78) 67 (54-81) 72 (56-85) 
Any diuretic therapy, % 85.9% 86.1% 67.1% 63.7% 81.0% 82.1% 
ACEi or ARB, % 95.2% 94.4% 90.1% 91.1% 87.6% 87.0% 
Aldosterone antagonists, % 8.1% 8.3% 6.4% 5.3% 9.9% 13.9% 
Digoxin, % 53.6% 55.5% 26.4% 24.7% 17.1% 25.2% 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats/minute; GFR, glomerular filtration rate; HF, heart failure; IQR, 
interquartile range; LVEF, left-ventricular ejection fraction; NYHA, New York Heart Association.   
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Supplementary Table C: Baseline LVEF and hazard for all-cause and cardiovascular mortality 
 
All-cause mortality Cardiovascular death 
N (events / patients HR, 95% CI; p-value N (events / patients HR, 95% CI; p-value 
Sinus rhythm; per 5% lower 
LVEF at baseline 
2,160 / 14,261 1.24, 1.21-1.28; p<0.0001 1,768 / 14,260 1.20, 1.22-1.30; p<0.0001 
Atrial fibrillation; per 5% lower 
LVEF at baseline 
609 / 3,034 1.09, 1.03-1.15; p=0.002 498 / 3,034 1.10, 1.05-1.18; p<0.0001 
Adjusted hazard ratio (HR) analysed using a one-stage Cox regression model, with studies as strata.  See also Supplementary Figure B. 
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Supplementary Table D: Mode of death by baseline LVEF category in sinus rhythm  
Baseline 
LVEF 
<20% 20-25% 26-34% 35-39% 40-49% ≥50% 
Randomised 
allocation 
PLC BB PLC BB PLC BB PLC BB PLC BB PLC BB 
Ischaemic cardiomyopathy 
All-cause 
mortality* 
229 / 727 
(31.5%) 
180 / 756 
(23.8%) 
254 / 1258 
(20.2%) 
208 / 1314 
(15.8%) 
248 / 1697 
(14.6%) 
214 / 1778 
(12.0%) 
97 / 776 
(12.5%) 
62 / 786 
(7.9%) 
29 / 262 
(11.1%) 
19 / 260 
(7.3%) 
9 / 105 
(8.6%) 
13 / 104 
(12.5%) 
CV death 
201 / 727 
(27.6%) 
156 / 756 
(20.6%) 
220 / 1258 
(17.5%) 
181 / 1314 
(13.8%) 
207 / 1697 
(12.2%) 
172 / 1778 
(9.7%) 
78 / 776 
(10.1%) 
53 / 786 
(6.7%) 
22 / 262 
(8.4%) 
12 / 260 
(4.6%) 
6 / 105 
(5.7%) 
9 / 104 
(8.7%) 
Sudden death 
103 / 727 
(14.2%) 
83 / 756 
(11.0%) 
117 / 1258 
(9.3%) 
86 / 1314 
(6.5%) 
121 / 1697 
(7.1%) 
88 / 1778 
(4.9%) 
36 / 776 
(4.6%) 
29 / 786 
(3.7%) 
10 / 262 
(3.8%) 
4 / 260 
(1.5%) 
2 / 105 
(1.9%) 
3 / 104 
(2.9%) 
HF-related 
death 
73 / 727 
(10.0%) 
45 / 756 
(6.0%) 
66 / 1258 
(5.2%) 
63 / 1314 
(4.8%) 
52 / 1697 
(3.1%) 
48 / 1778 
(2.7%) 
20 / 776 
(2.6%) 
9 / 786 
(1.1%) 
6 / 262 
(2.3%) 
3 / 260 
(1.2%) 
1 / 105 
(1.0%) 
1 / 104 
(1.0%) 
Non-CV death 
10 / 727 
(1.4%) 
18 / 756 
(2.4%) 
16 / 1258 
(1.3%) 
14 / 1314 
(1.1%) 
21 / 1697 
(1.2%) 
19 / 1778 
(1.1%) 
9 / 776 
(1.2%) 
4 / 786 
(0.5%) 
4 / 262 
(1.5%) 
3 / 260 
(1.2%) 
1 / 105 
(1.0%) 
1 / 104 
(1.0%) 
Non-ischaemic cardiomyopathy 
All-cause 
mortality* 
136 / 508 
(26.8%) 
118 / 561 
(21.0%) 
99 / 644 
(15.4%) 
82 / 669 
(12.3%) 
113 / 782 
(14.5%) 
81 / 819 
(9.9%) 
16 / 189 
(8.5%) 
18 / 178 
(10.1%) 
6 / 21 
(28.6%) 
2 / 32 
(6.3%) 
2 / 16 
(12.5%) 
1 / 19 
(5.3%) 
CV death 
99 / 508 
(19.5%) 
80 / 561 
(14.3%) 
72 / 644 
(11.2%) 
61 / 669 
(9.1%) 
83 / 782 
(10.6%) 
54 / 819 
(6.6%) 
11 / 189 
(5.8%) 
15 / 178 
(8.4%) 
4 / 21 
(19.0%) 
1 / 32 
(3.1%) 
1 / 16 
(6.3%) 
0 / 19 
(0.0%) 
Sudden death 
48 / 508 
(9.4%) 
39 / 561 
(7.0%) 
38 / 644 
(5.9%) 
27 / 669 
(4.0%) 
48 / 782 
(6.1%) 
27 / 819 
(3.3%) 
9 / 189 
(4.8%) 
5 / 178 
(2.8%) 
2 / 21 
(9.5%) 
1 / 32 
(3.1%) 
1 / 16 
(6.3%) 
0 / 19 
(0.0%) 
HF-related 
death 
38 / 508 
(7.5%) 
28 / 561 
(5.0%) 
26 / 644 
(4.0%) 
17 / 669 
(2.5%) 
22 / 782 
(2.8%) 
15 / 819 
(1.8%) 
2 / 189 
(1.1%) 
6 / 178 
(3.4%) 
1 / 21 
(4.8%) 
0 / 32 
(0.0%) 
0 / 16 
(0.0%) 
0 / 19 
(0.0%) 
Non-CV death 
8 / 508 
(1.6%) 
9 / 561 
(1.6%) 
8 / 644 
(1.2%) 
7 / 669 
(1.0%) 
11 / 782 
(1.4%) 
13 / 819 
(1.6%) 
3 / 189 
(1.6%) 
1 / 178 
(0.6%) 
0 / 21 
(0.0%) 
0 / 32 
(0.0%) 
0 / 16 
(0.0%) 
1 / 19 
(5.3%) 
BB, beta-blockers; CV, cardiovascular; LVEF, left-ventricular ejection fraction; PLC, placebo.  * Includes deaths due to an unknown cause. Note that some deaths were ascribed to 
unknown causes and therefore are attributed neither to cardiovascular or non-cardiovascular deaths. 
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Supplementary Table E: Mode of death by baseline LVEF category in atrial fibrillation  
Baseline LVEF <20% 20-25% 26-34% 35-39% 40-49% ≥50% 
Randomised 
allocation 
PLC BB PLC BB PLC BB PLC BB PLC BB PLC BB 
Ischaemic cardiomyopathy 
All-cause 
mortality* 
47 / 141 
(33.3%) 
47 / 126 
(37.3%) 
49 / 224 
(21.9%) 
44 / 219 
(20.1%) 
60 / 302 
(19.9%) 
72 / 279 
(25.8%) 
29 / 120 
(24.2%) 
18 / 113 
(15.9%) 
9 / 50 
(18.0%) 
14 / 54 
(25.9%) 
3 / 26 
(11.5%) 
3 / 26 
(11.5%) 
CV death 
45 / 141 
(31.9%) 
39 / 126 
(31.0%) 
41 / 224 
(18.3%) 
37 / 219 
(16.9%) 
51 / 302 
(16.9%) 
60 / 279 
(21.5%) 
26 / 120 
(21.7%) 
14 / 113 
(12.4%) 
7 / 50 
(14.0%) 
9 / 54 
(16.7%) 
1 / 26 
(3.8%) 
2 / 26 
(7.7%) 
Sudden death 
17 / 141 
(12.1%) 
16 / 126 
(12.7%) 
22 / 224 
(9.8%) 
18 / 219 
(8.2%) 
19 / 302 
(6.3%) 
28 / 279 
(10.0%) 
15 / 120 
(12.5%) 
7 / 113 
(6.2%) 
1 / 50 
(2.0%) 
3 / 54 
(5.6%) 
0 / 26 
(0.0%) 
0 / 26 
(0.0%) 
HF-related 
death 
25 / 141 
(17.7%) 
21 / 126 
(16.7%) 
13 / 224 
(5.8%) 
11 / 219 
(5.0%) 
24 / 302 
(7.9%) 
18 / 279 
(6.5%) 
6 / 120 
(5.0%) 
5 / 113 
(4.4%) 
2 / 50 
(4.0%) 
1 / 54 
(1.9%) 
0 / 26 
(0.0%) 
0 / 26 
(0.0%) 
Non-CV death 
2 / 141 
(1.4%) 
5 / 126 
(4.0%) 
4 / 224 
(1.8%) 
5 / 219 
(2.3%) 
4 / 302 
(1.3%) 
4 / 279 
(1.4%) 
0 / 120 
(0.0%) 
2 / 113 
(1.8%) 
1 / 50 
(2.0%) 
2 / 54 
(3.7%) 
1 / 26 
(3.8%) 
1 / 26 
(3.8%) 
Non-ischaemic cardiomyopathy 
All-cause 
mortality* 
24 / 106 
(22.6%) 
31 / 121 
(25.6%) 
42 / 213 
(19.7%) 
28 / 211 
(13.3%) 
50 / 255 
(19.6%) 
31 / 265 
(11.7%) 
5 / 70 
(7.1%) 
8 / 64 
(12.5%) 
5 / 17 
(29.4%) 
5 / 25 
(20.0%) 
1 / 11 
(9.1%) 
1 / 10 
(10.0%) 
CV death 
18 / 106 
(17.0%) 
24 / 121 
(19.8%) 
34 / 213 
(16.0%) 
25 / 211 
(11.8%) 
34 / 255 
(13.3%) 
22 / 265 
(8.3%) 
4 / 70 
(5.7%) 
3 / 64 
(4.7%) 
4 / 17 
(23.5%) 
2 / 25 
(8.0%) 
1 / 11 
(9.1%) 
0 / 10 
(0.0%) 
Sudden death 
11 / 106 
(10.4%) 
7 / 121 
(5.8%) 
18 / 213 
(8.5%) 
16 / 211 
(7.6%) 
20 / 255 
(7.8%) 
8 / 265 
(3.0%) 
2 / 70 
(2.9%) 
1 / 64 
(1.6%) 
1 / 17 
(5.9%) 
0 / 25 
(0.0%) 
1 / 11 
(9.1%) 
0 / 10 
(0.0%) 
HF-related 
death 
6 / 106 
(5.7%) 
14 / 121 
(11.6%) 
9 / 213 
(4.2%) 
6 / 211 
(2.8%) 
7 / 255 
(2.7%) 
8 / 265 
(3.0%) 
2 / 70 
(2.9%) 
1 / 64 
(1.6%) 
2 / 17 
(11.8%) 
2 / 25 
(8.0%) 
0 / 11 
(0.0%) 
0 / 10 
(0.0%) 
Non-CV death 
0 / 106 
(0.0%) 
0 / 121 
(0.0%) 
2 / 213 
(0.9%) 
1 / 211 
(0.5%) 
4 / 255 
(1.6%) 
3 / 265 
(1.1%) 
0 / 70 
(0.0%) 
1 / 64 
(1.6%) 
0 / 17 
(0.0%) 
2 / 25 
(8.0%) 
0 / 11 
(0.0%) 
1 / 10 
(10.0%) 
BB, beta-blockers; CV, cardiovascular; LVEF, left-ventricular ejection fraction; PLC, placebo.  * Includes deaths due to an unknown cause. Note that some deaths were ascribed to 
unknown causes and therefore are attributed neither to cardiovascular or non-cardiovascular deaths. 
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Supplementary Table F: Absolute mortality difference and observed change in LVEF according to aetiology in sinus rhythm 
Classification ‘Reduced’ LVEF 
‘Mid-range’ 
LVEF 
‘Preserved’ LVEF 
LVEF at baseline <20% 20-25% 26-34% 35-39% 40-49% ≥50% 
Sinus rhythm: Ischaemic aetiology 
Change in absolute mortality; beta-
blockers vs placebo (95% CI) † 
n=1483  
-7.7%  
(-12.2% to -3.1%) 
n=2572  
-4.4%  
(-7.3% to -1.4%) 
n=3475  
-2.6%  
(-4.8% to -0.3%) 
n=1562  
-4.6%  
(-7.6% to -1.6%) 
n=522  
-3.8%  
(-8.7% to +1.2%) 
n=209  
+3.9%  
(-4.4% to +12.2%) 
Change in LVEF from baseline to follow-
up; mean difference (SE) beta-blockers vs 
placebo‡ 
n=593 
+3.1% (0.6%) 
n=667 
+3.3% (0.6%) 
n=1070 
+3.0% (0.5%) 
n=277 
+4.4% (1.0%) 
n=227 
+2.5% (1.2%) 
n=177 
+0.6% (1.3%) 
Sinus rhythm: Non-ischaemic aetiology 
Change in absolute mortality; beta-
blockers vs placebo (95% CI) † 
n=1069  
-5.7%  
(-10.9% to -0.6%) 
n=1313  
-3.1%  
(-6.8% to +0.6%) 
n=1601  
-4.6%  
(-7.8% to -1.4%) 
n=367  
+1.6%  
(-4.3% to +7.6%) 
n=53  
-22.3%  
(-43.4% to -1.3%) 
n=35  
-7.2%  
(-26.3% to +11.8%) 
Change in LVEF from baseline to follow-
up; mean difference (SE) beta-blockers vs 
placebo‡ 
n=513 
+6.2% (0.9%) 
n=401 
+5.6% (1.0%) 
n=530 
+6.2% (0.9%) 
n=98 
+6.3% (2.0%) 
n=24 
-4.2% (4.3%) 
n=24 
-4.4% (4.5%) 
† Median follow-up of 1.3 years (IQR 0.8-1.9) 
‡ Median 1.0 years after baseline assessment (IQR 0.3-2.0) 
CI = confidence interval; LVEF = left ventricular ejection fraction; SE = standard error of the mean difference. 
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Figure legends 
Figure 1: Hazard of all-cause mortality across the spectrum of LVEF 
Hazard ratio and 95% confidence intervals for all-cause mortality according to baseline left 
ventricular ejection fraction (LVEF), relative to a patient with an LVEF of 35%.  Hazard ratios are 
fitted using a Cox proportional hazards regression model, adjusted for treatment, age, gender, 
previous myocardial infarction, systolic blood pressure, heart rate, use of angiotensin 
inhibitors/receptor blockers and diuretics, and stratified by study. 
 
Figure 2: Beta-blockers versus placebo according to baseline LVEF in sinus rhythm 
Intention to treat, one-stage Cox proportional hazards model in categories of left ventricular ejection 
fraction (LVEF) at baseline, adjusted for age, gender, previous myocardial infarction, systolic blood 
pressure, heart rate, and use of angiotensin inhibitors/receptor blockers and diuretics.  ‘n’ is the 
number of individual patients analysed from double-blind, randomized controlled trials for the 
primary outcomes with complete case data. 
 
Figure 3: Beta-blockers versus placebo in sinus rhythm according to heart failure phenotype 
Kaplan Meier plots for unadjusted (A) all-cause mortality and (B) cardiovascular mortality 
according to baseline left ventricular ejection fraction (LVEF).  * Similar results in post-hoc 
analysis when excluding patients with an LVEF reported as exactly 40% from the 40-49% group: 
(A) log-rank p=0.030 and (B) log-rank p=0.039; n=147 placebo and n=143 beta-blockers. 
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Figure 4: Beta-blockers versus placebo according to baseline LVEF in atrial fibrillation 
Intention to treat, one-stage Cox proportional hazards model in categories of left ventricular ejection 
fraction (LVEF) at baseline, adjusted for age, gender, previous myocardial infarction, systolic blood 
pressure, heart rate, and use of angiotensin inhibitors/receptor blockers and diuretics.  ‘n’ is the 
number of individual patients analysed from double-blind, randomized controlled trials for the 
primary outcomes. 
 
Figure 5: Observed change in LVEF in survivors 
Change in left ventricular ejection fraction (LVEF) from baseline in patients who survived to 
follow-up, with median time between measurements of 1.0 years (interquartile range 0.3-2.0 years).  
Those with follow-up LVEF were older in age compared to those without follow-up LVEF (67 
[IQR 56-74] versus 64 [55-71] years, respectively), but with similar baseline LVEF (27% [20-33] 
versus 27% [21-33]) and frequency of ischaemic cardiomyopathy (65% versus 67%).  The variance 
for each category of change in LVEF (beta-blockers versus placebo) is presented in Table 3.  (A) 
Sinus rhythm; n=4,601 patients.  (B) Atrial fibrillation; n=996. 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 35 of 35 
Supplementary Figure A: Study flowchart 
Note that left ventricular ejection fraction (LVEF) entry criteria for trials were often based on an 
assessment of LVEF that preceded enrolment.  Hence at randomization or core laboratory 
assessment, some patients had LVEF above these inclusion/exclusion criteria and were available for 
analysis in this individual patient-level dataset.  (a) Patients with stable heart failure and ischemic 
wall motion abnormalities.  (b) Either LVEF ≤35%, or a hospital admission for heart failure within 
12 months regardless of LVEF.  
 
Supplementary Figure B: Crude and age-adjusted primary events according to baseline 
LVEF 
Kaplan Meier survival curves for observed events according to baseline LVEF category regardless 
of heart rhythm.  For both all-cause mortality and cardiovascular death, the trend test using a 
stratified log-rank analysis was p<0.0001. 
 
Supplementary Figure C: Scatterplot of change versus baseline LVEF 
Change in LVEF plotted against baseline value for individual patients in sinus rhythm or atrial 
fibrillation (n=5,597).  Dashed red line is the linear regression line. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
10 20 30 40 50 60
0.5
1.0
1.5
2.0
2.5
LVEF at baseline (%)
H
a
z
a
r
d
 
r
a
t
i
o
(
c
o
m
p
a
r
e
d
 
t
o
 
L
V
E
F
 
3
5
%
)
Figure 1 eps
0.1
1
10
B
e
t
a
-
b
l
o
c
k
e
r
s
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
:
 
A
d
j
u
s
t
e
d
 
h
a
z
a
r
d
 
r
a
t
i
o
 
&
 
9
5
%
 
C
I
<20% 26-34% 35-39% 40-49% ≥50%20-25%
All-cause mortality
CV death
Sinus rhythm
Primary outcomes
CV hospitalisation
CV death/hospitalisation
Secondary outcomes
n=2,531              n=3,862            n=5,043              n=1,919               n=570                 n=241
Figure 2 eps
Ca
r
d
i
o
v
a
s
c
u
l
a
r
 
m
o
r
t
a
l
i
t
y
1 2 3
Years
00 1 2 3
Years
Placebo
Beta-blockers
LVEF <40%, sinus rhythm LVEF 40-49%, sinus rhythm LVEF ≥50%, sinus rhythm
0 1 2 3
Years
Log-rank p<0.001 Log-rank p=0.022* Log-rank p=0.57
Placebo
Number at risk
Beta-blocker
0%
10%
20%
30%
40%
C
a
r
d
i
o
v
a
s
c
u
l
a
r
 
m
o
r
t
a
l
i
t
y
0%
10%
20%
30%
40%
C
a
r
d
i
o
v
a
s
c
u
l
a
r
 
m
o
r
t
a
l
i
t
y
0%
10%
20%
30%
40%
123 97 43 13
121 97 45 10
292 211 65 15
283 199 63 11
6861 4680 1673 678
6580 4281 1404 525
A
l
l
-
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
1 2 3
Years
00 1 2 3
Years
Placebo
Beta-blockers
LVEF <40%, sinus rhythm LVEF 40-49%, sinus rhythm LVEF ≥50%, sinus rhythm
0 1 2 3
Years
Log-rank p<0.001 Log-rank p=0.042* Log-rank p=0.51
Placebo
Number at risk
Beta-blocker
0%
10%
20%
30%
40%
A
l
l
-
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
0%
10%
20%
30%
40%
A
l
l
-
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
0%
10%
20%
30%
40%
123 97 43 13
121 97 45 10
292 211 65 15
283 199 63 11
6861 4680 1673 678
6581 4282 1405 526
All-cause mortality
Cardiovascular mortality
A
B
Figure 3 eps
0.1
1
10
B
e
t
a
-
b
l
o
c
k
e
r
s
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
:
 
A
d
j
u
s
t
e
d
 
h
a
z
a
r
d
 
r
a
t
i
o
 
&
 
9
5
%
 
C
I
<20% 26-34% 35-39% 40-49% ≥50%20-25%
 n=492                 n=867               n=1,093               n=363                  n=146                  n=73
All-cause mortality
CV death
Atrial brillation
Primary outcomes
CV hospitalisation
CV death/hospitalisation
Secondary outcomes
Figure 4 eps
Ch
a
n
g
e
 
i
n
 
L
V
E
F
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
%
)
Baseline LVEF (%)
<2
0%
20
-2
5%
26
-3
4%
35
-3
9%
40
-4
9%
≥5
0%
-5
0
5
10
C
h
a
n
g
e
 
i
n
 
L
V
E
F
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
%
)
Baseline LVEF (%)
<2
0%
20
-2
5%
26
-3
4%
35
-3
9%
40
-4
9%
≥5
0%
-5
0
5
10Placebo Beta-blocker Placebo Beta-blocker
Sinus rhythm Atrial !brillationA B
Figure 5 eps
Missing baseline electrocardiogram (n=118)
Heart block (n=510)
Paced rhythm (n=616)
Missing baseline LVEF (n=91)
Individual patient data
n=18,637
MDC
n=317
CIBIS
n=627
US-HF
n=906
ANZ
n=409
CIBIS-II
n=2,537
MERIT-HF
n=3,895
COPERNICUS
n=1,856
CAPRICORN
n=1,895
BEST
n=2,551
CHRISTMAS
n=376
SENIORS
n=1,943
Inclusion: ≤40% Inclusion: ≤40% Inclusion: ≤35% Inclusion: ≤45% Inclusion: ≤35%
see (b)see (a)Inclusion: ≤35%Inclusion: ≤40%Inclusion: <25%
Inclusion: ≤40%
n=17,312
Sinus rhythm
n=14,262
Atrial !brillation
n=3,050
Supplementary Figure A eps
-20%
-10%
0%
10%
20%
30%
40%
C
h
a
n
g
e
 
i
n
 
e
j
e
c
t
i
o
n
 
f
r
a
c
t
i
o
n
0% 10% 20% 30% 40% 50% 60% 70% 80%
Ejection fraction at baseline
Supplementary Figure C eps
Pr
o
p
o
r
t
i
o
n
 
w
i
t
h
 
e
v
e
n
t
P
r
o
p
o
r
t
i
o
n
 
w
i
t
h
 
e
v
e
n
t
All-cause mortality
Crude Age-adjusted
Cardiovascular death
0%
10%
20%
30%
40%
50%
0 1 2 3
0%
10%
20%
30%
40%
50%
0 1 2 3
Time (years) Time (years)
<20%
20-25%
26-34%
35-39%
40-49%
≥50%
<20%
20-25%
26-34%
35-39%
40-49%
≥50%
P
r
o
p
o
r
t
i
o
n
 
w
i
t
h
 
e
v
e
n
t
P
r
o
p
o
r
t
i
o
n
 
w
i
t
h
 
e
v
e
n
t
Crude Age-adjusted
0%
10%
20%
30%
40%
50%
0 1 2 3
0%
10%
20%
30%
40%
50%
0 1 2 3
Time (years) Time (years)
<20%
20-25%
26-34%
35-39%
40-49%
≥50%
<20%
20-25%
26-34%
35-39%
40-49%
≥50%
A
B
Supplementary Figure B eps
